Profile photo Szolt Sebestyen

Szolt Sebestyen

Associate Professor

Biography

  1. Biograpy: Obtained his PhD in Hungary at University of Debrecen, where he became fascinated by biophysical techniques that he learned to use to study molecular interactions in living cells. He was further trained in the Babraham Institute In Cambridge (UK) and later at the ErasmusMC in Rotterdam (NL) where he as postdoctoral fellow has studied the molecular needs of genetic engineering of T cells for the immunotherapy of cancer. He continued his career at the UMCU in Utrecht, where he was appointed in 2014 as staff member of Section Applied within the Laboratory of Translational Immunology. He is currently focusing on the developement of novel gamma delta T cell-based immunotherapies and the better understanding of innate T cell and tumour cell interactions.  Reserach interest:  Tumour recognition of innate immune cells, Immune receptors , Genetic engineering

Research groups

Tumor Immunology

Research aim

Our research aims to revolutionise cancer treatment by advancing innovative immunotherapies, ensuring safer, more effective therapies, and improving patient outcomes, ultimately transforming lives through cutting-edge translational cancer research.

Go to group

Recent publications

BEHAV3D Maria Alieva, Mario Barrera Román, Sam de Blank, Diana Petcu, Amber L. Zeeman, Noël M.M. Dautzenberg, Annelisa M. Cornel, Cesca van de Ven, Rob Pieters, Monique L. den Boer, Stefan Nierkens, Friso G.J. Calkoen, Hans Clevers, Jürgen Kuball, Zsolt Sebestyén, Ellen J. Wehrens, Johanna F. Dekkers, Anne C. Rios
Nature protocols, 2024, vol. 19, p.2052-2084
Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML Vania Lo Presti, Angelo Meringa, Ester Dunnebach, Alice van Velzen, Aida Valera Moreira, Ronald W Stam, Rishi S Kotecha, Anja Krippner-Heidenreich, Olaf T Heidenreich, Maud Plantinga, Annelisa Cornel, Zsolt Sebestyen, Jurgen Kuball, Niek P van Til, S Nierkens
Journal for ImmunoTherapy of Cancer, 2024, vol. 12
Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1 Annelisa M Cornel, Loutje van der Sman, Jip T van Dinter, Marta Arrabito, Ester Dunnebach, Marliek van Hoesel, Thomas A Kluiver, Ana P Lopes, Noël M M Dautzenberg, Linde Dekker, Jorik M van Rijn, Denise A M H van den Beemt, Juliane L Buhl, Aimee du Chatinier, Farnaz Barneh, Yuyan Lu, Luca Lo Nigro, Anja Krippner-Heidenreich, Zsolt Sebestyén, Jurgen Kuball, Esther Hulleman, Jarno Drost, Sebastiaan van Heesch, Olaf T Heidenreich, Weng Chuan Peng, Stefan Nierkens
Journal for ImmunoTherapy of Cancer, 2024, vol. 12
CRISPR screens decode cancer cell pathways that trigger γδ T cell detection Murad R Mamedov, Shane Vedova, Jacob W Freimer, Avinash Das Sahu, Amrita Ramesh, Maya M Arce, Angelo D Meringa, Mineto Ota, Peixin Amy Chen, Kristina Hanspers, Vinh Q Nguyen, Kirsten A Takeshima, Anne C Rios, Jonathan K Pritchard, Jürgen Kuball, Zsolt Sebestyen, Erin J Adams, Alexander Marson
Nature, 2023, vol. 621, p.188-195
Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells Patricia Hernández-López, Eline van Diest, Peter Brazda, Sabine Heijhuurs, Angelo Meringa, Lauren Hoorens van Heyningen, Caterina Riillo, Caroline Schwenzel, Marina Zintchenko, Inez Johanna, Mara J T Nicolasen, Astrid Cleven, Thomas A Kluiver, Rosemary Millen, Jiali Zheng, Froso Karaiskaki, Trudy Straetemans, Hans Clevers, Remco de Bree, Hendrik G Stunnenberg, Weng Chuan Peng, Jeanine Roodhart, Susana Minguet, Zsolt Sebestyén, Dennis X Beringer, Jürgen Kuball
Nature immunology, 2023, vol. 25, p.88-101
Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit I. Johanna, A. Daudeij, F. Devina, C. Nijenhuis, B. Nuijen, B. Romberg, C. de Haar, J. Haanen, H. Dolstra, E. Bremer, Z. Sebestyen, T. Straetemans, I. Jedema, J. Kuball
Immuno-Oncology and Technology, 2023, vol. 20